The Alzheimer’s Innovation Fund founded by the Vettel family provides critical seed funding to promising research projects aimed at Alzheimer’s prevention.
MESSAGE FROM MATT AND JENNA VETTEL
Alzheimer's is a devastating disease that impacts countless families—ours included. We understand the urgency of the moment and want to do our part to change the course of this disease for future generations.
The Alzheimer Center team at Brigham and Women’s Hospital (BWH), led by Drs. Dennis J. Selkoe, Reisa A. Sperling, and Kirk R. Daffner, is pioneering groundbreaking research efforts aimed at Alzheimer’s disease prevention. They are leading the first prevention trial for at-risk, clinically normal older adults while working to identify the earliest signs of the disease to ultimately prevent it from developing in the first place.
Like so many of you, we are eager to move this research forward. And we know philanthropy is the key. Even though BWH is one of the top recipients of funding from the National Institutes of Health, research grants take years for approval with only about 30% receiving funding.
To help fill this gap, our family has donated $1 million to establish the Alzheimer’s Innovation Fund at BWH to fuel early-stage research aimed at Alzheimer’s prevention.
Below is additional information about the magnitude of Alzheimer’s disease, as well as details about our new fund. You can partner with us by making a gift, or contact Ginny Fuller in the BWH Development Office at firstname.lastname@example.org or 617-424-4329 to learn more.
Thank you for joining with us to change the future of this disease.
Matt and Jenna Vettel
MAGNITUDE OF THE PROBLEM
Our rapidly aging population, combined with the fact that the average age of diagnosis is 74, creates the perfect storm for an Alzheimer’s epidemic. Consider the facts:
- Every 68 seconds, an American is diagnosed with Alzheimer’s
- Alzheimer’s affects more than 5 million Americans—with that number expected to triple by 2050
- The New England Journal of Medicine estimates the current total annual societal cost of dementia to be $42,000 to $56,000 per patient
- The Alzheimer’s Association estimates the cost of caring for Alzheimer's patients in the U.S. to be $226 billion in 2015—with the cost rising to $1.2 trillion by 2050
- Of the 10 leading causes of death in the U.S., Alzheimer’s is the only one without an effective disease-modifying therapy
Compounding this epidemic is the immeasurable physical and emotional toll that Alzheimer’s inflicts on patients and caregivers. There is no time to waste in establishing this critical investment for our future.
INTRODUCING THE ALZHEIMER'S INNOVATION FUND
In just the past few years, emerging technologies have revolutionized the way Alzheimer’s is understood. Research questions that were once completely elusive are now more attainable than ever before. To build on this momentum and help advance this progress, the Vettel family established the Alzheimer’s Innovation Fund at BWH. Our goal is to:
- Provide critical seed funding to test and reward early high-risk, high-reward concepts
- Fill funding gaps for innovative research projects
Fund the most promising ideas that will stop the progression of this
AT THE FOREFRONT OF RESEARCH AND CARE
The world-renowned Alzheimer Center team at BWH is working tirelessly to put an end to this tragic disease. With more than three decades of research, BWH has built a solid infrastructure of tools, technology, and people. Today, the BWH team of more than 250 dedicated Alzheimer’s experts partners with collaborators across the U.S. and in more than 12 countries to expand and accelerate our understanding of this disease. Read more.
ALZHEIMER'S INNOVATION FUND LEADERSHIP
DENNIS J. SELKOE, MD
Dennis J. Selkoe, MD, is co-director of the Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital and the Coates Professor of Neurology at Harvard Medical School.
REISA A. SPERLING, MD, MMSc
Reisa A. Sperling, MD, MMSc, is director of the Center for Alzheimer Research and Treatment at Brigham and Women's Hospital and professor of neurology at Harvard Medical School.
HOW TO HELP
To learn more about the strides BWH is making to eradicate Alzheimer’s disease and ways you can make a difference, please contact Ginny Fuller, director of development, at email@example.com or 617-424-4329.